Form 4: Ikena Oncology Director Acquires Stock Options

Jean-Francois Formela, a director at Ikena Oncology, acquired stock options for 17,520 shares at an exercise price of $1.75 on June 7, 2024.

Summary

• On June 7, 2024, Jean-Francois Formela, a director of Ikena Oncology, Inc., acquired stock options for 17,520 shares.
• The exercise price for these options is $1.75 per share.
• The options vest fully on the earlier of June 7, 2025, or the date of the next annual meeting, contingent upon continued service as a director.
• The options expire on June 6, 2034.
• Formela is a member of Atlas Venture Associates X, LLC and will transfer any economic benefit from the sale of these shares to Atlas Venture Life Science Advisors, LLC.
• Formela disclaims beneficial ownership of these securities except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align the interests of management with those of shareholders.

Key Dates